SCHEMBL4548414

SCHEMBL4548414

COC(=O)CCc1cnn(-c2ccc([N+](=O)[O-])cn2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.43
HCAR2 Q8TDS4 1/20 0.41
MAPT P10636 6/20 0.40
ALDH1A1 P00352 3/20 0.39
CYP1A2 P05177 2/20 0.39
GAA P10253 1/20 0.39
LMNA P02545 1/20 0.39
ALOX12 P18054 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
POLB P06746 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
PTGS2 P35354 1/20 0.37
NPBWR1 P48145 1/20 0.37
MCHR1 Q99705 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4548413 0.81 HCAR2 (0.44) HCAR2CYP2C9
SCHEMBL4548416 0.81 CYP2C19 (0.42) CYP2C19HCAR2MAPTALDH1A1CYP1A2
SCHEMBL10312536 0.81 HCAR2 (0.45) CYP2C19HCAR2MAPTALDH1A1CYP1A2
SCHEMBL4548415 0.80 HCAR2 (0.42) CYP2C19HCAR2MAPTALDH1A1CYP1A2
SCHEMBL4548417 0.77 MAPT (0.48) MAPTALDH1A1CYP1A2GAALMNA
SCHEMBL1350027 0.73 MAPT (0.57) MAPTALDH1A1POLBRAB9AKMT2A
SCHEMBL3134703 0.73 GAA (0.59) CYP2C19MAPTALDH1A1GAALMNA
SCHEMBL4548418 0.73 MAPT (0.51) MAPTALDH1A1CYP1A2GAALMNA
SCHEMBL3138319 0.72 MAPT (0.49) CYP2C19MAPTALDH1A1LMNANPSR1
SCHEMBL3127860 0.72 PLA2G4A (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. (US) 2012-07-12 US disclosed
US-8168649-B2 Niacin receptor agonists, compositions containing such compounds and methods of treatment Merk Sharp & Dohme Corp. (US) 2012-05-01 US disclosed
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME LLC 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, GPR119 CYP2C19 618/4885HCAR2 2/4885MAPT 2721/4885
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, FFAR1 CYP2C19 619/4885HCAR2 2/4885MAPT 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.